The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
NSAIDs and incident Alzheimer’s disease. the Rotterdam study
Abstract
Recent studies suggest that the use of nonsteroidal anti-inflammatory drugs (NSAIDs) may reduce the risk for Alzheimer's disease (AD). We investigated the relation of NSAID use over a 10-year period and the risk for incident AD using a nested case-control design in the population-based Rotterdam Study. The study was performed in 306 subjects; 74 Alzheimer patients diagnosed according to NINCDS-ADRDRA criteria and 232 age and sex-matched controls. NSAID use was abstracted from general practitioners' medical records and expressed as cumulative prescription days. The relative risk for AD associated with long-term use (> or = 2 months) was 0.95 (95% CI: 0.46-1.99) as compared to nonusers, after controlling for possible confounders. In a separate examination, subjects who had more than 6 months of prescription days had a reduced relative risk for AD (RR = 0.74 (95% CI: 0.20-2.72). In an age-stratified analysis the effect in long-term users was evident in those aged 85 and under; 0.53 (95% CI: 0.15-1.77). All risk estimates were lower when the last 2 years of exposure were excluded from the analyses. Our point estimates in subjects younger than 85 years and in subjects using NSAIDs for 6 months or more are consistent with the hypothesis that long-term use of NSAIDs reduces the risk for AD. However, overall there was no association between NSAID use and the risk for incident AD.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Second, retrospective studies demonstrate that sustained NSAID treatment during mid-life significantly decreases the risk of AD (109, 110).”
From The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease (2018) · cites this paper as [110]
Citations
Cites
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132
Research works printed but not linked: 17
- Andersen, 1995, Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer’s disease? The Rotterdam Study, Neurology, 45, 1441, 10.1212/WNL.45.8.1441 · DOI
- Breitner, 1994, Inverse association of anti-inflammatory treatments and Alzheimer’s disease, Neurology, 44, 227, 10.1212/WNL.44.2.227 · DOI
- Breteler, 1992, Epidemiology of Alzheimer’s disease, Epidemiol. Rev., 14, 59, 10.1093/oxfordjournals.epirev.a036092 · DOI
- Broe, 1990, A case-control study of Alzheimer’s disease in Australia, Neurology, 40, 1698, 10.1212/WNL.40.11.1698 · DOI
- Copeland, 1976, A semi-structured clinical interview for the assessment and diagnosis of mental state in the elderly: the Geriatric Mental State Schedule. I. Development and reliability, Psychol Med, 6, 439, 10.1017/S0033291700015889 · DOI
- Eikelenboom, 1994, Inflammatory mechanisms in Alzheimer’s disease, Trends Pharmacol. Sci., 15, 447, 10.1016/0165-6147(94)90057-4 · DOI
- Folstein, 1975, “Mini-mental State.” A practical method for grading the cognitive state of patients for the clinician, J. Psychiatr. Res., 12, 189, 10.1016/0022-3956(75)90026-6 · DOI · Paper page
- French, 1985, A case-control study of dementia of the Alzheimer’s type, Am. J. Epidemiol., 121, 414, 10.1093/oxfordjournals.aje.a114013 · DOI
- Graves, 1990, A case-control study of Alzheimer’s disease, Ann. Neurol., 28, 766, 10.1002/ana.410280607 · DOI
- Jenkinson, 1989, Rheumatoid arthritis and senile dementia of the Alzheimer’s type, Br. J. Rheumatol., 28, 86, 10.1093/rheumatology/28.1.86-b · DOI
- McGeer, 1989, Immune system response in Alzheimer’s disease, Can. J. Neurol. Sci., 816, 516, 10.1017/S0317167100029863 · DOI
- McGeer, 1992, Prevalence of dementia amongst elderly Japanese with leprosy, Dementia, 3, 146
- McGeer, 1990, Anti-Inflammatory drugs and Alzheimer’s disease, Lancet, 335, 1037, 10.1016/0140-6736(90)91101-F · DOI
- McKhann, 1984, Clinical diagnosis of Alzheimer’s disease, Neurology, 34, 939, 10.1212/WNL.34.7.939 · DOI · Paper page
- Myllykangas–Luosujarvi, 1994, Alzheimer’s disease and rheumatoid arthritis, Br. J. Rheumatol., 33, 501, 10.1093/rheumatology/33.5.501 · DOI
- Roth, 1986, CAMDEX. A standardized instrument for the diagnosis of mental disorders in the elderly with special reference to the early detection of dementia, Br. J. Psychiatry, 149, 698, 10.1192/bjp.149.6.698 · DOI · Paper page
- Van Muiswinkel, 1996, Do nonsteroidal anti-inflammatory drugs have a protective effect against dementia?, Drug Aging, 9, 1, 10.2165/00002512-199609010-00001 · DOI
Cited by
Sorted by citations
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
Yang, F., Lim, G. P., Begum, A. N., Ubeda, O. J., Simmons, M. R., Ambegaokar, S. S., Chen, P. P., Kayed, R., Glabe, C. G., Frautschy, S. A., et al. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m404751200 · Cited by 2,336
Lindsay, J. (2002) · American Journal of Epidemiology · doi:10.1093/aje/kwf074 · Cited by 1,261
Nonsteroidal Antiinflammatory Drugs and the Risk of Alzheimer's Disease
in 't Veld, B. A., Ruitenberg, A., Hofman, A., Launer, L. J., van Duijn, C. M., Stijnen, T., Breteler, M. M. B., & Stricker, B. H. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010178 · Cited by 1,196
Self-citationIn-vivo measurement of activated microglia in dementia
Cagnin, A., Brooks, D. J., Kennedy, A. M., Gunn, R. N., Myers, R., Turkheimer, F. E., Jones, T., & Banati, R. B. (2001) · The Lancet · doi:10.1016/s0140-6736(01)05625-2 · Cited by 1,054
Inflammation in Alzheimer Disease--A Brief Review of the Basic Science and Clinical Literature
Wyss-Coray, T., & Rogers, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006346 · Cited by 975
Ibuprofen Suppresses Plaque Pathology and Inflammation in a Mouse Model for Alzheimer's Disease
Lim, G. P., Yang, F., Chu, T., Chen, P., Beech, W. K., Teter, B., Tran, T., Ubeda, O. J., Ashe, K. H., Frautschy, S. A., et al. (2000) · Journal of Neuroscience · doi:10.1523/jneurosci.20-15-05709.2000 · Cited by 876
Dementia and Cognitive Impairment
Hugo, J., & Ganguli, M. (2014) · Clinics in Geriatric Medicine · doi:10.1016/j.cger.2014.04.001 · Cited by 990
SIRT1 Protects against Microglia-dependent Amyloid-β Toxicity through Inhibiting NF-κB Signaling
Chen, J., Zhou, Y., Mueller-Steiner, S., Chen, L.-F., Kwon, H., Yi, S., Mucke, L., & Gan, L. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m509329200 · Cited by 740
Etminan, M., Gill, S., & Samii, A. (2003) · BMJ · doi:10.1136/bmj.327.7407.128 · Cited by 511
Cribbs, D. H., Berchtold, N. C., Perreau, V., Coleman, P. D., Rogers, J., Tenner, A. J., & Cotman, C. W. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-179 · Cited by 499
Reactive oxygen species (ROS) play an important role in a rat model of neuropathic pain
Kim, H., Park, S., Zhou, J.-L., Taglialatela, G., Chung, K., Coggeshall, R., & Chung, J.-M. (2004) · Pain · doi:10.1016/j.pain.2004.06.008 · Cited by 451
“…and neurodegeneration in the aging brain and in some neurodegenerative diseases are widely regarded as at least a partial consequence of ROS damage associated with increased levels of pro-inflammatory cytokines (Coyle and Puttfarcken, 1993; Götz et al., 1994; In’t Veld et al., 1998; Jenner, 1994).”
BackgroundYin, F. (2023) · The FEBS Journal · doi:10.1111/febs.16344 · Cited by 441
Nonsteroidal Anti-Inflammatory Drugs for the Prevention of Alzheimer’s Disease: A Systematic Review
Szekely, C. A., Thorne, J. E., Zandi, P. P., Ek, M., Messias, E., Breitner, J. C. S., & Goodman, S. N. (2004) · Neuroepidemiology · doi:10.1159/000078501 · Cited by 402
Neuro-inflammation and anti-inflammatory treatment options for Alzheimer’s disease
Ozben, T., & Ozben, S. (2019) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2019.04.001 · Cited by 381
Reduced incidence of AD with NSAID but not H2receptor antagonists
Zandi, P. P., Anthony, J. C., Hayden, K. M., Mehta, K. M., Mayer, L. S., & Breitner, J. C. S. (2002) · Neurology · doi:10.1212/wnl.59.6.880 · Cited by 317
Miklossy, J. (2011) · Journal of Neuroinflammation · doi:10.1186/1742-2094-8-90 · Cited by 358
Microglia and neuroprotection: From in vitro studies to therapeutic applications
Polazzi, E., & Monti, B. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.06.009 · Cited by 269
Karran, E. H., & Hardy, J. (2014) · Annals of Neurology · doi:10.1002/ana.24188 · Cited by 279
Alzheimer's disease and type 2 diabetes: a critical assessment of the shared pathological traits
Chatterjee, S., & Mudher, A. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00383 · Cited by 270
Breteler, M. M. B. (2000) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2000.tb06399.x · Cited by 236
Self-citationIbuprofen effects on Alzheimer pathology and open field activity in APPsw transgenic mice
Lim, G. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00299-8 · Cited by 232
Martín-Moreno, A. M., Brera, B., Spuch, C., Carro, E., García‐García, L., Delgado, M., Pozo, M. A., Innamorato, N. G., Cuadrado, A., & CEBALLOS, M. L. D. (2012) · Journal of Neuroinflammation · doi:10.1186/1742-2094-9-8 · Cited by 250
Reduced prevalence of AD in users of NSAIDs and H2 receptor antagonists
Anthony, J. C., Breitner, J. C. S., Zandi, P. P., Meyer, M. R., Jurasova, I., Norton, M. C., & Stone, S. V. (2000) · Neurology · doi:10.1212/wnl.54.11.2066 · Cited by 222
The immunology of neurodegeneration
Czirr, E., & Wyss‐Coray, T. (2012) · Journal of Clinical Investigation · doi:10.1172/jci58656 · Cited by 218
“Additional evidence linking systemic inflammation with neurodegeneration comes from epidemiological studies, which show that prolonged use of nonsteroidal anti-inflammatory drugs (NSAIDs) reduces the risk of developing AD (32) or PD (33) by as much as 50%.”
NSAID use and dementia risk in the Cardiovascular Health Study*: Role of APOE and NSAID type
Szekely, C. A., Breitner, J. C. S., Fitzpatrick, A. L., Rea, T. D., Psaty, B. M., Kuller, L. H., & Zandi, P. P. (2008) · Neurology · doi:10.1212/01.wnl.0000284596.95156.48 · Cited by 204
Cao, Y., Chtarbanova, S., Petersen, A. J., & Ganetzky, B. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1306220110 · Cited by 214
Arendt, T. (2003) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2003.09.007 · Cited by 189
Asanuma, M., Nishibayashi-Asanuma, S., Miyazaki, I., Kohno, M., & Ogawa, N. (2001) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2001.00205.x · Cited by 190
Pasqualetti, P., Bonomini, C., Dal Forno, G., Paulon, L., Sinforiani, E., Marra, C., Zanetti, O., & Maria Rossini, P. (2009) · Aging Clinical and Experimental Research · doi:10.1007/bf03325217 · Cited by 172
The coxib NSAIDs: potential clinical and pharmacologic importance in veterinary medicine.
Bergh, M. S., & Budsberg, S. (2005) · Journal of Veterinary Internal Medicine · doi:10.1111/j.1939-1676.2005.tb02741.x · Cited by 161
Wardill, H. R., Mander, K. A., Sebille, Y. Z. A. V., Gibson, R. J., Logan, R. M., Bowen, J. M., & Sonis, S. T. (2016) · International Journal of Cancer · doi:10.1002/ijc.30252 · Cited by 182
Frodl, T., & Amico, F. (2013) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2012.12.013 · Cited by 150
Clinical aspects of inflammation in Alzheimer's disease
Rosenberg, P. B. (2005) · International Review of Psychiatry · doi:10.1080/02646830500382037 · Cited by 158
Lahiri, D. K., Maloney, B., Basha, R. M., Ge, Y. W., & Zawia, N. (2007) · Current Alzheimer Research · doi:10.2174/156720507780362164 · Cited by 134
Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions
Elmaleh, D. R., Farlow, M. R., Conti, P. S., Tompkins, R. G., Kundakovic, L., & Tanzi, R. E. (2019) · Journal of Alzheimer’s Disease · doi:10.3233/jad-190507 · Cited by 129
The Inflammatory Continuum of Traumatic Brain Injury and Alzheimer’s Disease
Kokiko-Cochran, O. N., & Godbout, J. P. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00672 · Cited by 128
“Second, retrospective studies demonstrate that sustained NSAID treatment during mid-life significantly decreases the risk of AD (109, 110).”
BackgroundThe molecular basis of the prevention of Alzheimer’s disease through healthy nutrition
Steele, M. L., Stuchbury, G., & Münch, G. W. (2006) · Experimental Gerontology · doi:10.1016/j.exger.2006.06.002 · Cited by 110
Rosenberger, T., Villacreses, N., Hovda, J., Bosetti, F., Weerasinghe, G. R., Wine, R. N., Harry, G., & Rapoport, S. I. (2004) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.02246.x · Cited by 123
Putative role of neuronal 5-lipoxygenase in an aging brain
Manev, H., Uz, T., Sugaya, K., & Qu, T. (2000) · The FASEB Journal · doi:10.1096/fj.14.10.1464 · Cited by 113
“Recent clinical studies point to the beneficial effects of antiinflammatory treatments in Alzheimer’s patients (56, 57).”
Disease modifying therapy for AD?1
Golde, T. E. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.04211.x · Cited by 117
Nonsteroidal anti‐inflammatory drug use and the risk of cognitive impairment and Alzheimer's disease
Côté, S., Carmichael, P., Verreault, R., Lindsay, J., Lefèbvre, J., & Laurin, D. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2011.03.012 · Cited by 126
Relation of NSAIDs to incident AD, change in cognitive function, and AD pathology
Arvanitakis, Z., Grodstein, F., Bienias, J. L., Schneider, J. A., Wilson, R. S., Kelly, J. F., Evans, D. A., & Bennett, D. A. (2008) · Neurology · doi:10.1212/01.wnl.0000313813.48505.86 · Cited by 116
Hippocampal expression of murine IL-4 results in exacerbation of amyloid deposition
Chakrabarty, P., Tianbai, L., Herring, A., Ceballos-Diaz, C., Das, P., & Golde, T. E. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-36 · Cited by 116
Hirohata, M., Ono, K., Naiki, H., & Yamada, M. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.07.004 · Cited by 132
Do NSAIDs prevent Alzheimer's disease? And, if so, why? The epidemiological evidence
Zandi, P. P. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00297-4 · Cited by 101
Melah, K. E., Lu, S. Y.-F., Hoscheidt, S. M., Alexander, A. L., Adluru, N., Destiche, D. J., Carlsson, C. M., Zetterberg, H., Blennow, K., Okonkwo, O. C., et al. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-150897 · Cited by 109
Hormetic effects of curcumin: What is the evidence?
Aghili‐Moghaddam, N. S., Nosrati‐Oskouie, M., Butler, A. E., Petit, P. X., Barreto, G. E., & Sahebkar, A. (2018) · Journal of Cellular Physiology · doi:10.1002/jcp.27880 · Cited by 110
The unsolved relationship of brain aging and late-onset Alzheimer disease
Kern, A., & Behl, C. (2009) · Biochimica et Biophysica Acta (BBA) - General Subjects · doi:10.1016/j.bbagen.2009.07.016 · Cited by 108
Kukull, W. A., & Bowen, J. D. (2002) · Medical Clinics of North America · doi:10.1016/s0025-7125(02)00010-x · Cited by 110
Leoutsakos, J., Muthén, B., Breitner, J. C. S., & Lyketsos, C. G. (2011) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2723 · Cited by 109
Hewett, S. J., Bell, S. C., & Hewett, J. A. (2006) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2005.04.011 · Cited by 91
Apoptosis modulators in the therapy of neurodegenerative diseases
Deigner, H., Haberkorn, U., & Kinscherf, R. (2000) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.9.4.747 · Cited by 94
“This study showed that overall there was no association between NSAID use and the incidence of AD [88].”
ResultThe pentraxins: possible role in Alzheimer's disease and other innate inflammatory diseases.
Mcgeer, E., Yasojima, K., Schwab, C., & McGeer, P. (2001) · Neurobiology of Aging · doi:10.1016/s0197-4580(01)00288-3 · Cited by 86
Cole, G. M., & Frautschy, S. A. (2010) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/187152710791011991 · Cited by 85
Isoprenoids and Alzheimer's disease: A complex relationship
Cole, S. L., & Vassar, R. J. (2006) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.11.007 · Cited by 71
Nonsteroidal anti-inflammatory drug use and Alzheimer's disease risk: the MIRAGE Study
Yip, A. G., Green, R. C., Huyck, M., Cupples, L. A., Farrer, L. A., & for the MIRAGE Study Group (2005) · BMC Geriatrics · doi:10.1186/1471-2318-5-2 · Cited by 79
Anti-amyloid-β protein agents for the treatment of Alzheimer’s disease: an update on emerging drugs
Lozupone, M., Solfrizzi, V., D’Urso, F., Di Gioia, I., Sardone, R., Dibello, V., Stallone, R., Liguori, A., Ciritella, C., Daniele, A., et al. (2020) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2020.1808621 · Cited by 77
Moussa, N., & Dayoub, N. (2023) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2023.101729 · Cited by 92
“For example, the Rotterdam Study reported that NSAIDs have effects on dementia risk and could reduce it (In ’t Veld et al., 1998).”
Neuroinflammation and Alzheimer Disease: Clinical and Therapeutic Implications
Eikelenboom, P., Rozemüller, A. J. M., Hoozemans, J. J. M., Veerhuis, R., & van Gool, W. A. (2000) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200000001-00009 · Cited by 78
The Chemistry of Neurodegeneration: Kinetic Data and Their Implications
Pavlin, M., Repič, M., Vianello, R., & Mavri, J. (2015) · Molecular Neurobiology · doi:10.1007/s12035-015-9284-1 · Cited by 75
Klegeris, A., & McGeer, P. (2000) · Journal of Leukocyte Biology · doi:10.1002/jlb.67.1.127 · Cited by 73
Philippens, I. H. C. H. M., Ormel, P. R., Baarends, G., Johansson, M., Remarque, E. J., & Doverskog, M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160673 · Cited by 83
Do nonsteroidal antiinflammatory drugs reduce the risk of Alzheimer's disease?
Breitner, J., & Zandi, P. (2001) · New England Journal of Medicine · doi:10.1056/nejm200111223452110 · Cited by 72
Apetz, N., Münch, G. W., Govindaraghavan, S., & Gyengési, E. (2014) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/1871527313666140917110635 · Cited by 73
“Further evidence was provided by several population-based cohorts and case-control studies that revealed a decreased risk for AD when comparing (long-term) NSAID-users to non-users [94-99].”
BackgroundDetrait, E., Danis, B., Lamberty, Y., & Foerch, P. (2014) · Neurochemistry International · doi:10.1016/j.neuint.2014.04.001 · Cited by 70
“Elevation of TNF-a 63 64 65 66 67 68 69 70 71 72 73 74 75 76 77 Fifteen years ago, it was demonstrated that non-steroidal antiinflammatory drugs (NSAIDs) decreased the risk of developing Alzheimer’s disease (In ‘t Veld et al., 1998).”
BackgroundCornelius, C., Fastbom, J., Winblad, B. G., & Viitanen, M. H. (2004) · Neuroepidemiology · doi:10.1159/000075957 · Cited by 66
Anti-inflammatory and Immune Therapy for Alzheimers Disease: Current Status and Future Directions
Walker, D., & Lue, L.-F. (2007) · Current Neuropharmacology · doi:10.2174/157015907782793667 · Cited by 66
Neuroinflammation and tumor necrosis factor signaling in the pathophysiology of Alzheimer’s disease
Tansey, M. G., & McAlpine (2008) · Journal of Inflammation Research · doi:10.2147/jir.s4397 · Cited by 55
New Anti-inflammatory Treatment Strategy in Alzheimer’s Disease
Sugaya, K., Uz, T., Kumar, V., & Manev, H. (2000) · The Japanese Journal of Pharmacology · doi:10.1254/jjp.82.85 · Cited by 65
Dementia / Alzheimer's Disease
Lindsay, J., & Anderson, L. (2004) · BMC Women s Health · doi:10.1186/1472-6874-4-s1-s20 · Cited by 41
NSAIDs for the Chemoprevention of Alzheimer’s Disease
Szekely, C. A., Town, T., & Zandi, P. P. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_11 · Cited by 53
Emerging drugs to reduce abnormal β-amyloid protein in Alzheimer’s disease patients
Panza, F., Seripa, D., Solfrizzi, V., Imbimbo, B. P., Lozupone, M., Leo, A., Sardone, R., Gagliardi, G., Lofano, L., Creanza, B. C., et al. (2016) · Expert Opinion on Emerging Drugs · doi:10.1080/14728214.2016.1241232 · Cited by 61
“Therefore, the protective effect of these NSAIDs, showed in epidemiological studies reporting lower rates of AD among people who had been taking these drugs for chronic treatment of inflammatory conditions [47,48], was then attributed to this γ-secretase modulating activity [41], and not to their COX inhibition.”
BackgroundThe Role of Eicosanoids in Alzheimer’s Disease
Biringer, R. G. (2019) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph16142560 · Cited by 65
“Non-steroidal anti-inflammatory agents (NSAIDs) are known inhibitors of cyclooxygenases and there are numerous reports that show unequivocally that long term use of NSAIDs is associated with a reduction in the risk of developing AD [35,36].”
BackgroundTratamento farmacológico da doença de Alzheimer
Forlenza, O. V. (2005) · Archives of Clinical Psychiatry (São Paulo) · doi:10.1590/s0101-60832005000300006 · Cited by 56
“Estudos epidemiológicos conduzidos no final década passada sugeriram que o uso prolongado de antiinflamatórios não-esteróides estaria associado a uma redução de na incidência de DA, porém não afetando o risco de demência vascular (in t’ Veld et al., 1998; 2001).”
BackgroundNeuroinflammation as a Potential Therapeutic Target in Alzheimer’s Disease
Liu, P., Wang, Y., Sun, Y., & Peng, G. (2022) · Clinical Interventions in Aging · doi:10.2147/cia.s357558 · Cited by 94
“The Rotterdam Study revealed a significantly decreased risk of AD among NSAIDs users of 2 or more years in duration (ie, 80% sparing).(16) The Multi-Institutional Research in Alzheimer’s Genetic Epidemiology (MIRAGE) study revealed a risk reduction of 36% and protective effects of NSAIDs exposure to be more pronounced…”
BackgroundClinical trials for preventing post stroke cognitive impairment
Ankolekar, S., Geeganage, C. M., Anderton, P., Hogg, C., & Bath, P. M. (2010) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2010.08.052 · Cited by 58
“Further, the effect of interventions may take time to develop as seen with antihypertensives in preventing stroke, and with NSAIDS and dementia [52].”
Sparing of age-related macular degeneration in rheumatoid arthritis
McGeer, P. L., & Sibley, J. T. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.02.003 · Cited by 51
Jonker, C., Comijs, H. C., & Smit, J. H. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00188-4 · Cited by 48
Veld, B. A. I. (2002) · Epidemiologic Reviews · doi:10.1093/epirev/mxf001 · Cited by 56
“…1.59), NSAID + aspirin Brooks et al., 1998 (43) NSAID (current use), aspirin Interview Prospective cohort study Community (8.4% = 53) Community NS Cornelius et al., 1998 (51) NSAID taken regularly Interview Prospective populationbased cohort study Cohort (n = 110) Cohort 0.8 (0.4, 1.9) in ’t…”
InfluentialSelf-citationWu, S., Basile, A. S., & Barger, S. W. (2007) · Current Alzheimer Research · doi:10.2174/156720507781077241 · Cited by 47
Klaver, D. W., Wilce, M. C. J., Cui, H., Hung, A. C., Gasperini, R., Foa, L. C., & Small, D. H. (2010) · Biological Chemistry · doi:10.1515/bc.2010.089 · Cited by 41
Klegeris, A., & McGeer, P. (2000) · Experimental Neurology · doi:10.1006/exnr.2000.7517 · Cited by 44
Verapamil is associated with an increased risk of cancer in the elderly: the Rotterdam study.
Beiderbeck-Noll, A. B., Sturkenboom, M., van der Linden, P. D., Herings, R. M., Hofman, A., Coebergh, J., Leufkens, H., & Stricker, B. H. C. (2003) · European Journal of Cancer · doi:10.1016/s0959-8049(02)00157-0 · Cited by 42
Self-citationLee, H., Villacreses, N., Rapoport, S., & Rosenberger, T. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02786.x · Cited by 41
Gahtan, E., & Overmier, J. B. (2001) · Physiology & Behavior · doi:10.1016/s0031-9384(01)00471-1 · Cited by 40
Petegnief, V., Saura, J., DeGregorio‐Rocasolano, N., & Paul, S. M. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00046-x · Cited by 39
Lowering the risk of Alzheimer's disease: Evidence‐based practices emerge from new research
Jedrziewski, M. K., Lee, V. M. ‐., & Trojanowski, J. Q. (2005) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2005.09.007 · Cited by 41
Targeting innate immunity to protect and cure Alzheimer’s disease: opportunities and pitfalls
Cisbani, G., & Rivest, S. (2021) · Molecular Psychiatry · doi:10.1038/s41380-021-01083-4 · Cited by 44
“between use of NSAIDs and risk for incident of AD [53].”
BackgroundTreatments for Alzheimer Disease
Potyk, D. K. (2005) · Southern Medical Journal · doi:10.1097/01.smj.0000166671.86815.c1 · Cited by 37
The role of microglia in Alzheimer’s disease: friend or foe?
Schenk, D., & Yednock, T. A. (2002) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00034-9 · Cited by 32
Harnessing Immunoproteostasis to Treat Neurodegenerative Disorders
Golde, T. E. (2019) · Neuron · doi:10.1016/j.neuron.2019.02.027 · Cited by 45
Alzheimer's disease risk alleles in TREM2 illuminate innate immunity in Alzheimer's disease
Golde, T. E., Streit, W. J., & Chakrabarty, P. (2013) · Alzheimer s Research & Therapy · doi:10.1186/alzrt178 · Cited by 39
Watterson, D., Mirzoeva, S., Guo, L.-Y., Whyte, A., Bourguignon, J., Hibert, M., Haiech, J., & Eldik, L. V. V. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00053-5 · Cited by 33
Scorer, C. A. (2001) · Drug Discovery Today · doi:10.1016/s1359-6446(01)02042-6 · Cited by 32
Ibuprofen treatment modifies cortical sources of EEG rhythms in mild Alzheimer’s disease
Babiloni, C., Frisoni, G. B., Percio, C. D., Zanetti, O. O., Bonomini, C., Cassetta, E., Pasqualetti, P., Miniussi, C., Rosas, M. D., Valenzano, A. A., et al. (2009) · Clinical Neurophysiology · doi:10.1016/j.clinph.2009.02.005 · Cited by 33
Asanuma, M., & Miyazaki, I. (2006) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.6.9.1313 · Cited by 28
Du, Y.-S., Chen, X., Wei, X.-L., Bales, K., Berg, D., Paul, S., Farlow, M., Maloney, B., Ge, Y.-W., & Lahiri, D. (2005) · Molecular Brain Research · doi:10.1016/j.molbrainres.2005.02.001 · Cited by 28
Inflammation and aging: Can endocannabinoids help?
Marchalant, Y., Brothers, H. M., & Wenk, G. L. (2008) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2008.02.004 · Cited by 27
“Long term use of anti-inflammatory drugs has been hypothesized to counteract with these processes and thus protect against the disease; epidemiological evidence supports the long term use of NSAIDs to reduce the prevalence of AD (Andersen et al., 1995; In’T Veld et al., 1998).”
BackgroundWolfson, C. M., Perrault, A., Moride, Y., Esdaile, J. M., Abenhaim, L., & Momoli, F. (2002) · Neuroepidemiology · doi:10.1159/000048621 · Cited by 27
Metadata
- Authors
- In ’t Veld, B. A., Launer, L. J., Hoes, A. W., Ott, A., Hofman, A., Breteler, M. M. B., & Stricker, B. H. C.
- Affiliations
- Erasmus MC (NL)
- Utrecht University (NL)
- Dutch Health Care Inspectorate (NL)
- Corresponding author
- Launer, L.J
- Venue
- Neurobiology of Aging
- Publisher
- Elsevier BV
- Published
- 1998-11
- Volume
- 19
- Issue
- 6
- Pages
- 607-611
- ISSN
- 0197-4580 (ISSN-L)
- OpenAlex
- W1965756304
- Cited by
- 145
- References
- 0
- Citations by year
- 2024: 2 · 2023: 2 · 2022: 4 · 2021: 4 · 2020: 1 · 2019: 6 · 2018: 2 · 2017: 3 · 2016: 6 · 2015: 1 · 2014: 5 · 2013: 4 · 2012: 5
- FWCI
- 7.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Neurobiology of Aging (publishedVersion)
- PubMed (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Rivm (National Institute for Public Health and the Environment) (submittedVersion)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Keywords
- nonsteroidal anti-inflammatory drugs, Alzheimer's disease, long-term NSAID use, Rotterdam Study
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Anti-Inflammatory Agents, Non-Steroidal, Female, Humans, Male, Middle Aged, Risk, Logistic Models, Case-Control Studies
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review